Skip to main content

Table 1 Demographic and baseline characteristics

From: Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma

Ā 

SFC (n = 33)

FP/M (n = 33)

Mean age in years (SD)

36.3 (8.11)

34.4 (7.71)

No of females (%)

18 (55%)

14 (42%)

Mean duration of asthma in years (SD)

21.1 (12.7)

18.4 (9.7)

Mean AM PEF (L/min) (SD)

412 (95)

422 (103)

Mean % predicted mean AM PEF (SD)

84 (12)

83 (14)

Mean clinic FEV1 (L) (SD)

2.65 (0.77)

2.76 (0.60)

% predicted clinic FEV1 (SD)

75 (9)

76 (7)

Geometric mean PC20 (mg/ml)

0.28

0.32

Median dose of pre-study ICS (BDP equivalent) (mcg) (range)

400 (200 to 400)

400 (100 to 400)

  1. AM, morning; FEV1, forced expiratory volume in 1 second; FP/M, fluticasone propionate plus montelukast; n, number; PEF, peak expiratory flow; SD, standard deviation; SFC, salmeterol plus fluticasone propionate